Navigation Links
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Date:1/14/2008

tients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS, may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfec
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
11. Schering-Plough Reports Top-Line Results of the IDEAL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" ... today announced financial results for its first quarter ended ... months ended December 31, 2014, revenue was $1,336,685. Operating ... $229,820 or $0.02 per share.  Covalon,s ... am very pleased with the significant progress we have ...
(Date:2/27/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, announced today that Keith ... present live at VirtualInvestorConferences.com on March 5th. ... for this Company update," said Mr. Murphy. "We ... of the exVive3D Liver, Bioprinted Human Tissue, commercialization ...
(Date:2/27/2015)... Inc. (NASDAQ: UPI ), a medical device company ... treat voiding dysfunctions, today announced that it will participate ... 10, 2015. Rob Kill , President and CEO, ... present at 4:00 p.m. Pacific Time and meet with ... Ritz Carlton in Laguna Niguel, CA. ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2
... May 8 AstraZeneca (NYSE:,AZN) today announced the ... the U.S. Food and Drug Administration (FDA) for ... for the,treatment of generalized anxiety disorder (GAD), including ... approval has been sought for an,atypical antipsychotic medicine ...
... May 7 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ... a Phase 1 clinical trial of a drug ... compounds to treat psychiatric disorders.,The drug candidate is ... of a,common psychiatric disorder., "We are very ...
Cached Medicine Technology:AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3
(Date:2/28/2015)... 2015 A case management conference ( ... have been filed by law firms including Bernstein Liebhard ... March, the Firm notes. , According to a ... the federal litigation will meet on March 13, 2015 ... therapy treatments designed to raise levels of the male ...
(Date:2/28/2015)... On Thursday, February 26th, Forbes published an article ... To Steal Your Data , which stresses the ease with ... DIY phishing kit, or any kind of malware kit for ... point about how everyone’s cyber security is intertwined when it ... legitimate content management systems or blogs in order to install ...
(Date:2/28/2015)... Viejo, California (PRWEB) February 28, 2015 Developers ... the release of a new overlay plugin for Final Cut ... Film Studios. , “FCPX Overlay Chromatic gives users total control ... said Christina Austin, CEO of Pixel Film Studios. “FCPX Overlay ... maintaining an easy to use interface.” , FCPX Overlay Chromatic ...
(Date:2/28/2015)... Plugin creators from Pixel Film Studios have ... customizable transition pack made specifically for Final ... total control over 30 transition presets built exclusively for ... Studios. “TransFold Volume 2 gives endless possibilities to any ... from Pixel Film Studios brings back folding screen transitions ...
(Date:2/28/2015)... 28, 2015 My Shiney Hiney® LLC., the ... team to Las Vegas, Nevada for the annual ASD Market ... of the leading consumer-goods tradeshows and My Shiney Hiney will ... event. My Shiney Hiney can be found at booth number ... for the at-home personal hygiene brush and cleansing system exclusively ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2
... fossilized dinosaurs, with wide-open mouth, head thrown back and ... typical of brain damage and asphyxiation, according to ... the posture, which has puzzled palaeontologists for ages, is ... feathered dinosaur and the proposed link between dinosaurs and ...
... salinity could forewarn of climate change in 10 to ... results, presented at a recent European Science Foundation (ESF) ... stimulates deep-water circulation, while a diluting of the waters ... far more important role that we first thought, said ...
... Akt2/PKB, a fat metabolism regulatory protein, and its molecular partner, ... ,The study was conducted by a team of researchers ... School of Medicine. ,When a person eats, insulin ... stop forming glucose and burn fat. However in the case ...
... if the tag of being the country's greenest and cleanest city ... to its cap - it will become the first smoke-free city ... to get the city declared smoke free by July 1. ... smoking areas at all public places and buildings to ensure that ...
... are not taking enough vitamin D, a fact that ... according to a landmark study conducted by Creighton University ... study followed 1,179 healthy, postmenopausal women from rural eastern ... of vitamin D3 nearly three times the U.S. governments ...
... iodine-containing contrast agents (nonionic contrast media), are rare in ... researchers from the University of Michigan Medical Center and ... ,'A major, if not the main, risk associated ... Such reactions can be mild; for example, hives or ...
Cached Medicine News:Health News:Dinos may Have Died in Agonizing Death Throes of Asphyxiation 2Health News:Fluctuations in Ocean Salinity Could Forewarn of Climate Change 2Health News:Chandigarh to Become India's First Smoke-free City 2Health News:Vitamin D Reduces Cancer Risk 2Health News:Newer Contrast Agents Safe for Children 2
Cushing pituitary spoons, malleable copper, silver plated....
... the T.L.I.F. market as the premium banana-shaped implant. ... history and the amazing success of the Devex ... to be king of the jungle amongst T.L.I.F. ... in height. The footprint is 28 mm x ...
... Implant system. Material that has a modulus ... The result is an implant that meets ... while optimizing the fusion environment through an ... design with 5 and 10 degrees of ...
... anterior column support for single or multilevel ... L5. The system consists of one or ... are stacked to a desired height, accommodating ... Reinforced Polymer material emulates the biomechanical properties ...
Medicine Products: